Session Type: ACR Poster Session C
Session Time: 9:00AM-11:00AM
Disease activity in large vessel vasculitis (LVV) is traditionally assessed by clinical and serologic (ESR, CRP) parameters. Imaging assessment, including 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET), may be useful to monitor LVV. The study objective was to determine the impact of tocilizumab, infliximab and methotrexate (MTX) on disease activity in LVV as assessed by clinical, serologic, and imaging-based parameters.
Patients with GCA or TAK were recruited into a prospective, observational cohort involving ≥2 FDG-PET/CT scans at 6-month intervals. Clinical assessment [physician global assessment (PGA, range 0-10)], serologic assessment (CRP-mg/L, ESR-mm/hr), and imaging assessment [PET Vascular Activity Score (PETVAS)] was determined at each visit. PETVAS is a global summary score of arterial FDG uptake assessed qualitatively relative to liver activity in 9 vascular beds, ranging from 0 to 27 with higher scores indicating more vascular inflammation. Clinical and imaging assessments were performed blinded to each other. Wilcoxon signed rank test was used to compare changes in PGA, CRP, ESR, and PETVAS between interval visits in response to treatments.
Fourteen subjects with GCA were treated with tocilizumab. Prior to treatment, every patient had clinical and PET scan activity. There was significant reduction in PGA (2.5 vs 0, p<0.01), CRP (6.8 vs 0.5, p<0.01), ESR (22.5 vs 4.5, p<0.01), and PETVAS (25.0 vs 22.0, p=0.01). PETVAS improved in 5 of 7 patients with GCA treated with tocilizumab. Despite significant improvement in PETVAS, only 2 of 14 patients (14%) had normalization of PET activity after treatment with tocilizumab. In contrast, clinical remission after tocilizumab occurred in most of these patients (n=10;71%). Most of the subjects were on glucocorticoids (GCs) and there was significant reduction the daily GC dose (p=0.01) at follow up.
Six subjects with TAK were treated with infliximab. All of them had clinically active disease and active PET scan at baseline. There was significant improvement in PGA (5.5 vs 2, p=0.03); however, four of six patients (67%) continued to have clinically active disease at follow up. All six patients had an improvement in PETVAS (21.0 vs 14.5, p=0.03). However, four of the six patients continued to have active vasculitis by PET at follow-up despite treatment and there was no significant change in CRP (24.9 vs 4.9, p=0.31) or ESR (32.5 vs 18.5, p=0.13). Daily GC dose was similar at baseline and follow up (p=0.5).
Treatment with MTX was studied in 12 patients (TAK=3, GCA=9). Variable response to MTX was observed without significant change in PGA (3 vs 0, p=0.09), CPR (5.8 vs 3.5, p=0.18), ESR (31 vs 19.5, p=0.33), or PETVAS (24 vs 18, p=0.31).
Imaging and clinical assessment of disease activity significantly improved but rarely normalized in response to tocilizumab in GCA and TNF inhibitors in TAK. In contrast, methotrexate did not consistently improve clinical or imaging-based assessments of disease activity in LVV. These findings support a need to study the value of FDG-PET as a surrogate outcome measure of vascular activity in randomized clinical trials in LVV.
To cite this abstract in AMA style:Banerjee S, Quinn K, Gribbons KB, Rosenblum JS, Civelek A, Novakovich E, Bagheri A, Merkel PA, Ahlman MA, Grayson PC. Effect of Specific Treatments on Clinical, Serologic, and Imaging Assessments of Disease Activity in Large-Vessel Vasculitis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https://acrabstracts.org/abstract/effect-of-specific-treatments-on-clinical-serologic-and-imaging-assessments-of-disease-activity-in-large-vessel-vasculitis/. Accessed April 16, 2021.
« Back to 2018 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/effect-of-specific-treatments-on-clinical-serologic-and-imaging-assessments-of-disease-activity-in-large-vessel-vasculitis/